



Dedicated To Life

July 3, 2023

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad

Dear Sir / Madam,

We wish to inform that the Company has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad from March 20 to 24, 2023. The inspection has been classified as Voluntary Action Indicated (VAI). The EIR report indicates that the inspection is closed.

This may kindly be considered as a disclosure pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 24000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

